First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla., Jan. 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that enrollment is open at Erasmus Medical Center ("Erasmus MC") in a Phase 1b/2 clinical trial combining AIM's Ampligen® (rintatolimod) with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab ...

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have elected all four of the Company’s directors, Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and William M. Mitchell, at the Company’s 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) held today. AIM issued the following statement: “ We would like to thank our shareholders for their support and engagement throughout this process. Our Board and manage ...

AIM ImmunoTech Inc. (NYSE:AIM) Q3 2023 Earnings Call Transcript November 15, 2023 8:00 AM ET Company Participants Thomas Equels - Executive Vice Chairman, Chief Executive Officer and President Christopher McAleer - Scientific Officer Conference Call Participants Edward Woo - Ascendiant Capital Operator Hello, and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. [Operator Instructions] Following the presenta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2117 SW Highway 484, Ocala FL 34473 (Address of principal exe ...

AIM ImmunoTech Inc. (NYSE:AIM) Q2 2023 Earnings Conference Call August 15, 2023 8:30 AM ET Company Participants Thomas Equels - Executive Vice Chairman, Chief Executive Officer and President Christopher McAleer - Scientific Officer Conference Call Participants James Molloy - Alliance Global Partners Edward Woo - Ascendiant Capital Operator Hello and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in listen-only mode. [Operator I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2117 SW Highway 484, Ocala FL 34473 (Address of principal executive ...

AIM ImmunoTech Inc. (NYSE:AIM) Q1 2023 Earnings Conference Call May 16, 2023 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Ph.D. Scientific Officer Conference Call Participants James Molloy - Alliance Global Partners Ed Woo - Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. [Operator Instructions] Note that this webcast is being reco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2023 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2117 SW Highway 484, Ocala FL 34473 (Address of principal executive ...

AIM ImmunoTech Inc. (NYSE:AIM) Q4 2022 Earnings Conference Call April 3, 2023 8:30 AM ET Company Participants Thomas Equels - CEO Chris McAleer - Ph.D. Scientific Officer Conference Call Participants Jason McCarthy - Maxim Ed Woo - Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech Inaugural Fiscal Year 2022 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode. [Operator Instructions] Following the presentation, there will be ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction ...